65 results

Biomarker-Guided Antidepressant Selection (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 4 27 participants Weill Medical College of Cornell University

Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine

Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 468 participants University of Sao Paulo

Suicide Prevention, Ketamine, Crisis Response Plan

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 4 12 participants New York State Psychiatric Institute

Major Depressive Disorder (MDD)

Esketamine With or Without Integration Therapy for Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 20 participants University of Puerto Rico

Treatment-resistant Depression (TRD)

Ketamine for Postherpetic Neuralgia With Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 4 50 participants Huazhong University of Science and Technology

Depression Disorders, Herpetic Neuralgia

A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 47 participants Janssen Korea, Ltd., Korea

Depressive Disorder, Treatment-Resistant

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 30 participants Margaux M. Salas, PhD

Neuropathic Pain, PTSD

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 162 participants The George Institute

Treatment Resistant Depression

Ketamine-assisted Therapy for Advanced GI Cancer (opens ClinicalTrials.gov in a new tab)

Terminated Phase 4 1 participants Brian Anderson, MD

Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization

Neural Circuit Effects of Ketamine in Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 120 participants Icahn School of Medicine at Mount Sinai

Major Depressive Disorder

Positioning of Esketamine Treatment in the Real-world Management of Depression (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 162 participants Royal North Shore Hospital

Major Depressive Disorder

Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 110 participants Benha University

Depression, Anxiety

VA Aripiprazole vs Esketamine for Treatment Resistant Depression (opens ClinicalTrials.gov in a new tab)

Withdrawn Phase 4 0 participants VA Office of Research and Development

Depressive Disorder, Major

Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 60 participants University of Sao Paulo General Hospital

Cocaine Dependence

Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth (opens ClinicalTrials.gov in a new tab)

Active, not recruiting Phase 4 364 participants Peking University First Hospital

Prenatal Depression, Ketamine, Postpartum Depression

Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 205 participants Xiangya Hospital of Central South University

Lupus Nephritis

An EEG Study of Intravenous Ketamine for Major Depression Disorder (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 35 participants Ehave Inc.

Major Depressive Disorder

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 100 participants Massachusetts General Hospital

Major Depressive Disorder

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 123 participants Erika Forbes

Depression, Anhedonia

Safety and Efficacy Evaluation of S (+) - Ketamine in Children (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 3,000 participants Chinese PLA General Hospital

S-ketamine, Esketamine, Acute Pain, Postoperative Pain

Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 12 participants Taipei Veterans General Hospital, Taiwan

Treatment-resistant Depression, Major Depressive Disorder

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (opens ClinicalTrials.gov in a new tab)

Active, not recruiting Phase 4 136 participants Novartis Pharmaceuticals

Relapsing-Remitting Multiple Sclerosis

Effects of Esketamine on Postpartum Depression (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 500 participants Qinghai University

Postpartum Depression

Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 60 participants All India Institute of Medical Sciences, Bhubaneswar

Major Depressive Disorder

Influence of Δ9-tetrahydrocannabinol (THC) on Oxycodone Induced Ventilatory Depression in Healthy Volunteers (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 20 participants Leiden University Medical Center

Respiratory Depression, Cannabis Use, Opioid Use